{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T18:15:26Z","timestamp":1787508926299,"version":"build-2736575974"},"reference-count":0,"publisher":"Association of Basic Medical Sciences of FBIH","issue":"1","license":[{"start":{"date-parts":[[2025,3,19]],"date-time":"2025-03-19T00:00:00Z","timestamp":1742342400000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biomol Biomed"],"abstract":"<jats:p>Type 1 diabetes mellitus (T1DM) is a serious, chronic metabolic and autoimmune disease that affects millions globally. While insulin administration remains the most effective treatment, it is not a cure. Long-term therapies, such as immunotherapy, can be effective for some patients, but they have notable limitations and do not provide a permanent solution. As a result, current research has shifted towards stem cell-based therapies, which offer a potentially expandable and scalable source of pancreatic beta cells. These therapies aim to restore long-term endogenous \u03b2-cell function in all T1DM patients, provided they can avoid immune recognition and rejection by the host. In this review, we will discuss the latest first-in-human successes of stem cell therapies for T1DM. We will then explore stem cell-derived islet encapsulation technologies and hypoimmune stem cells, examining how they might overcome the need for immunosuppressive therapy. Additionally, we will provide a summary of recent and ongoing biopharmaceutical industry pipelines and clinical trials for stem cell therapies aimed at treating T1DM. These advances suggest that stem cell therapies offer a promising and highly effective approach to treating patients with this chronic disease. However, large-scale clinical trials over the long term are necessary to verify these early successes and assess the curative potential of stem cell therapy for T1DM.<\/jats:p>","DOI":"10.17305\/bb.2025.12222","type":"journal-article","created":{"date-parts":[[2025,3,19]],"date-time":"2025-03-19T09:09:56Z","timestamp":1742375396000},"page":"5-23","source":"Crossref","is-referenced-by-count":12,"title":["Recent advances in stem cell-based therapies for type 1 diabetes: A glimpse into the future"],"prefix":"10.17305","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-0912-5858","authenticated-orcid":false,"given":"Ahmed","family":"Hassanein","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3177-946X","authenticated-orcid":false,"given":"Saghir","family":"Akhtar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"6922","published-online":{"date-parts":[[2025,3,19]]},"container-title":["Biomolecules and Biomedicine"],"original-title":[],"link":[{"URL":"https:\/\/bjbms.org\/ojs\/index.php\/bjbms\/article\/download\/12222\/3819","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bjbms.org\/ojs\/index.php\/bjbms\/article\/download\/12222\/3819","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T23:06:06Z","timestamp":1761865566000},"score":1,"resource":{"primary":{"URL":"https:\/\/bjbms.org\/ojs\/index.php\/bjbms\/article\/view\/12222"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,19]]},"references-count":0,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,9,25]]}},"URL":"https:\/\/doi.org\/10.17305\/bb.2025.12222","relation":{},"ISSN":["2831-090X","2831-0896"],"issn-type":[{"value":"2831-090X","type":"electronic"},{"value":"2831-0896","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3,19]]}}}